ichor.bio
鏈接：https://www.ichor.bio/about/
ichorbio總部位于牛津，致力于開發(fā)最高質(zhì)量的試劑，成為研究級生物仿制藥和體內(nèi)抗體的最大供應(yīng)商，推動科學(xué)研究的進步。ichorbio目前可提供140多種價格j具競爭力的體內(nèi)研究抗體及相關(guān)同型對照抗體。同時，新增免疫檢查點分子相關(guān)產(chǎn)品、科研用生物仿制藥單克隆抗體、HLA-DR抗體、HLA-DQ抗體、體內(nèi)抗體標(biāo)記試劑盒，涵蓋癌癥研究、心血管研究、細胞生物學(xué)、表觀遺傳學(xué)和核信號、免疫學(xué)、微生物學(xué)、神經(jīng)科學(xué)、信號轉(zhuǎn)導(dǎo)和干細胞研究等各個研究領(lǐng)域，以滿足科學(xué)探索的各種需求。
癌癥 Cancer | 心血管 Cardiovascular | 細胞生物學(xué) Cell Biology |
免疫學(xué) Immunology | 微生物學(xué) Microbiology | 神經(jīng)科學(xué) Neuroscience |
信號轉(zhuǎn)導(dǎo) Transduction | 標(biāo)簽和細胞標(biāo)志物 Tags & Cell Markers | 干細胞 Stem Cells |
使用ichorbio產(chǎn)品發(fā)表的部分文獻：
發(fā)表年份 | 文章標(biāo)題 | 期刊名稱 | 作者 | 引用的ichorbio產(chǎn)品 |
2023 | Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. | Cell Stem Cell | Gravina et al. | ICH4002 |
2023 | Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation. | Int. J. Mol. Sci. | Mancusi et al. | ICH5025 |
2023 | A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors | Front Immunol. | Iadonato et al. | ICH4002 |
2023 | One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade | bioRxiv | Xu et al. | IHC1132 |
2023 | A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity | Journal of Experimental & Clinical Cancer Research | Lee et al. | ICH5015 |
2023 | Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer | Journal for ImmunoTheraphy of Cancer | Travelli et al. | ICH2248 |
2023 | M0bile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | Narsimhan et al. | ICH4011, ICH4009, ICH4019 |
2023 | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | Cao et al. | ICH1077, ICH1042, and ICH1043 |
2023 | Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration | Journal of Integrative Medicine | Yang et al. | ICH1128UL |
2023 | WNT4 promotes macrophage polarization via granulosa cell M-CSF and reduces granulosa cell apoptosis in endometriosis | Cytokine | Yuan et al. | ICH1026 |
FAQ
1.低內(nèi)毒素和超低內(nèi)毒素有什么區(qū)別？
答：ichorbio生產(chǎn)兩種用于體內(nèi)使用的格式：低內(nèi)毒素和超低內(nèi)毒素。超低格式具有更高的純度，更低的內(nèi)毒素，更低的聚集，并且經(jīng)過了與將要使用的動物相關(guān)的病原體測試。
2.抗體如何儲存？效期多久？
答：遵循我們數(shù)據(jù)表上列出的存儲信息。只有在存儲溫度正確時才保證一年的使用效期。
3.抗體溶液中發(fā)現(xiàn)有沉淀物是什么？
答：環(huán)境條件，如溫度變化、凍結(jié)/解凍、運輸過程中的搖晃以及長期存儲可能導(dǎo)致抗體溶液出現(xiàn)沉淀或絮塊。絮塊通常是緩沖鹽從溶液中沉淀出來或者一小部分蛋白質(zhì)聚集。如果輕輕地反復(fù)倒置小瓶，應(yīng)該可以去除沉淀。如果不能去除，我們建議通過過濾或離心來去除絮塊。
對于過濾，建議使用無菌的0.2μM過濾器。對于離心，我們建議將抗體溶液轉(zhuǎn)移到無菌離心管中（不要在提供的冷凍瓶中離心），并在10k rpm下離心5分鐘。更建議使用過濾而不是離心，因為離心可能使樣品發(fā)熱的時間比過濾的方式長，而過濾則可以非?？焖俚赝瓿?。無論選擇哪種方法，都應(yīng)使用無菌過濾器、注射器、管子等，并在生物安全柜中操作，以確保溶液保持無菌。此外，使用這些方法可以去除沉淀而不會有顯著的蛋白質(zhì)損失。如果在離心或過濾后擔(dān)心損失，您可以檢查離心或過濾后的蛋白質(zhì)濃度，并將其與提供的CoA上的濃度進行比較。
4.稀釋抗體的最佳方法是什么？
答：可以使用與抗體配方w全相符的無菌1*PBS。在稀釋時，建議使用冷緩沖液，并通過在生物安全柜中操作以及使用無菌移液管頭、管子、注射器和緩沖液來保持無菌。應(yīng)避免將抗體稀釋到工作濃度并在4℃以上存儲超過一天。
更多其它產(chǎn)品詳情請查詢ichorbio網(wǎng)站或咨詢ichorbio中國代理上海起發(fā)。
下圖為ichorbio公司授權(quán)上海起發(fā)作為中國區(qū)域代理的授權(quán)書。
ichorbio熱賣產(chǎn)品
貨號 | 產(chǎn)品名稱 | 規(guī)格 | 品牌 |
ICH1132-100mg | Anti-Mouse PD-1 In Vivo Antibody – Low Endotoxin (RMP1-14) | 100mg | ichorbio |
ICH5025-1mg | Blinatumomab Biosimilar - Research Grade [ICH5025] | 1mg | ichorbio |
ICH1132-50mg | Anti-Mouse PD-1 In Vivo Antibody - Low Endotoxin (RMP1-14) | 50mg | ichorbio |
ICH1114-5mg | Anti-Mouse RANKL In Vivo Antibody - Low Endotoxin (IK22/5) | 5mg | ichorbio |
ICH5056-20mg | Abciximab Biosimilar - Research Grade | 20mg | ichorbio |
ICH1009-25mg | Bulk anti-Human CD14 antibody (UCHM-1) | 25mg | ichorbio |
ICH2255-25mg | Bulk Human IgG2 Isotype Control (IB2) | 25mg | ichorbio |
ICH5025-5mg | Blinatumomab Biosimilar - Research Grade | 5mg | ichorbio |
ICH4002-1mg | Alemtuzumab Biosimilar - Research Grade | 1mg | ichorbio |
ICH1002-25mg | Bulk anti-Human CD3 antibody (UCHT-1) | 25mg | ichorbio |
ICH1002-5mg | Bulk anti-Human CD3 antibody (UCHT-1) | 5mg | ichorbio |
ICH2249UL-5mg | Mouse IgG3 Isotype Control for In Vivo - Ultra Low Endotoxin (MG3-35) [ICH2249UL] | 5mg | ichorbio |
ICH5056-1mg | Abciximab Biosimilar - Research Grade | 1mg | ichorbio |
ICH1086-5mg | Anti-Mouse PD-L1 In Vivo Antibody - Low Endotoxin (10F.9G2) | 5mg | ichorbio |
ICH1075-5mg | Anti-Mouse CD155 In Vivo Antibody – Low Endotoxin (4.24) | 5mg | ichorbio |
ICH1015-25mg | Bulk anti-Human CD56 antibody (ERIC-1) | 25mg | ichorbio |
ICH5025-0.5mg | Blinatumomab Biosimilar - Research Grade [ICH5025] | 0.5mg | ichorbio |
ICH2254-100mg | Bulk Human IgG1 Isotype Control (IB1) [ICH2254] | 100mg | ichorbio |
ICH1086-100mg | Anti-Mouse PD-L1 In Vivo Antibody - Low Endotoxin (10F.9G2) | 100mg | ichorbio |
ICH1002-50mg | Bulk anti-Human CD3 antibody (UCHT-1) | 50mg | ichorbio |
ICH1002-100mg | Bulk anti-Human CD3 antibody (UCHT-1) | 100mg | ichorbio |
ICH1025-5mg | Bulk anti-Human HLA-DQ antibody (1a3) | 5mg | ichorbio |
ICH1024-5mg | Bulk anti-Human HLA-DP antibody (B7/21) | 5mg | ichorbio |
ICH1183-100mg | Mouse anti-Mouse PD-L1 antibody (10F.9G2) [ICH1183] | 100mg | ichorbio |
ICH2254LALA-5mg | Human IgG1 Isotype Control (IB1) LALA | 5mg | ichorbio |
ICH5070-1mg | Enfortumab Biosimilar - Research Grade | 1mg | ichorbio |
ICH1042-1mg | Anti-Mouse CD4 In Vivo Antibody - Low Endotoxin (GK1.5) | 1mg | ichorbio |
ICH2250-5mg | Mouse IgG2b Isotype Control for In Vivo – Low Endotoxin (MPC-11) | 5mg | ichorbio |
ICH1130-25mg | Anti-Mouse, Human CD45R In Vivo Antibody - Low Endotoxin (RA3-6B2) | 25mg | ichorbio |
ICH1172-25mg | Bulk anti-Human CCR5 antibody (HEK/1/85a/7a) | 25mg | ichorbio |
ICH1028-25mg | Bulk anti-Human CD119 antibody (GIR 208) | 25mg | ichorbio |
ICH4014-0.1mg | Ado-trastuzumab emtansine Biosimilar - Research Grade | 0.1mg | ichorbio |
ICH1094-25mg | Anti-Mouse CD120a In Vivo Antibody - Low Endotoxin (55R-170) | 25mg | ichorbio |
ICH1117-25mg | Anti-Mouse IL-1R In Vivo Antibody - Low Endotoxin (JAMA-147) | 25mg | ichorbio |
ICH1023-25mg | Bulk anti-Human MHC Class I antibody (W6/32) | 25mg | ichorbio |
ICH1007-25mg | Bulk anti-Human CD11b antibody (ICRF44) | 25mg | ichorbio |
ICH1114-25mg | Anti-Mouse RANKL In Vivo Antibody - Low Endotoxin (IK22/5) | 25mg | ichorbio |
ICH1011-25mg | Bulk anti-Human CD19 antibody (SJ25-C1) | 25mg | ichorbio |
ICH1040-25mg | Anti-Mouse CD3e In Vivo Antibody - Low Endotoxin (500A2) | 25mg | ichorbio |
ICH1032-25mg | Bulk anti-Human iNKT cell antibody (6B11) | 25mg | ichorbio |
ICH1196-25mg | Anti-Mouse CD134 In Vivo Antibody (OX-86) - Low Endotoxin | 25mg | ichorbio |
ICH1092-25mg | Anti-Mouse Dendritic Cells In Vivo Antibody - Low Endotoxin (33D1) | 25mg | ichorbio |
ICH1122-25mg | Anti-Mouse IFNAR1 In Vivo Antibody - Low Endotoxin (MAR1-5A3) | 25mg | ichorbio |
ICH1021-25mg | Bulk anti-Human EGFR antibody (EGFR.1) | 25mg | ichorbio |
ICH1206-25mg | Anti-Mouse IL-21R In Vivo Antibody (4A9) - Low Endotoxin | 25mg | ichorbio |
ICH2254-5mg | Bulk Human IgG1 Isotype Control (IB1) | 5mg | ichorbio |
ICH4005-20mg | Eculizumab Biosimilar - Research Grade | 20mg | ichorbio |
ICH1137-25mg | Anti-Mouse TNFR2 In Vivo Antibody - Low Endotoxin (TR75-54.7) | 25mg | ichorbio |
ICH1076-5mg | Anti-Mouse CD172a In Vivo Antibody - Low Endotoxin (P84) | 5mg | ichorbio |
ICH5025-0.1mg | Blinatumomab Biosimilar - Research Grade | 0.1mg | ichorbio |
